KGaA, the German firm that specialises in chemical, pharmaceutical
and life sciences sectors, is planning to divest its biosimilars
is in advanced stages of negotiations to divest the biosimilars
business and the transaction is expected to close in 2017,” said the company in its 2016 annual report. Biosimilar unit comes under Merck’s healthcare business vertical, which also comprises biopharma, consumer health and Allergopharma businesses.
are a small, but fast-growing part of the pharmaceutical
market. In 2016, biosimilars
sales are expected to reach $ 1.4 billion annually before growing to $ 8 billion in 2022, according to EvaluatePharma.
is developing a biosimilars
portfolio focused on oncology and autoimmune diseases through both in-house research and development expertise in biologics and partnerships with other biosimilar players. It has strategic alliances with India’s Dr Reddy’s
Laboratories to co-develop multiple cancer
drugs and with Bionovis in Brazil to supply the Brazilian market with biological products under the Productive Development Partnership (PDP) policy of the Brazilian Ministry of Health.
With Dr Reddy’s, Merck
signed a partnership agreement in June 2012 to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). As per the pact, Dr Reddy’s
was expected to lead early product development & complete phase I development, with Merck
taking over manufacturing of the compounds and leading phase III development.